 Alan Palestine
Concepts (688)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 71 | 2025 | 134 | 7.680 |
Why?
| | Panuveitis | 4 | 2023 | 7 | 3.130 |
Why?
| | Fluocinolone Acetonide | 4 | 2024 | 19 | 2.420 |
Why?
| | Uveitis, Intermediate | 4 | 2023 | 8 | 2.300 |
Why?
| | Visual Acuity | 30 | 2024 | 348 | 2.260 |
Why?
| | Cataract | 6 | 2023 | 213 | 2.200 |
Why?
| | Fluorescein Angiography | 20 | 2025 | 150 | 1.990 |
Why?
| | Glucocorticoids | 9 | 2024 | 593 | 1.910 |
Why?
| | Eye Infections, Bacterial | 5 | 2020 | 28 | 1.800 |
Why?
| | Tomography, Optical Coherence | 11 | 2025 | 213 | 1.780 |
Why?
| | Endophthalmitis | 6 | 2020 | 29 | 1.740 |
Why?
| | Retinopathy of Prematurity | 8 | 2020 | 141 | 1.740 |
Why?
| | Macular Edema | 5 | 2023 | 43 | 1.700 |
Why?
| | Scleritis | 4 | 2025 | 23 | 1.670 |
Why?
| | Corneal Ulcer | 2 | 2022 | 16 | 1.530 |
Why?
| | Vitrectomy | 8 | 2020 | 70 | 1.530 |
Why?
| | Geographic Atrophy | 9 | 2025 | 78 | 1.510 |
Why?
| | Macular Degeneration | 10 | 2024 | 164 | 1.500 |
Why?
| | Arthritis, Juvenile | 2 | 2022 | 56 | 1.240 |
Why?
| | Cytomegalovirus Retinitis | 6 | 2024 | 21 | 1.240 |
Why?
| | Vitreous Body | 15 | 2022 | 110 | 1.230 |
Why?
| | Ocular Hypertension | 4 | 2022 | 67 | 1.070 |
Why?
| | Cyclosporins | 31 | 1991 | 76 | 0.990 |
Why?
| | Corneal Transplantation | 5 | 2025 | 13 | 0.960 |
Why?
| | Wet Macular Degeneration | 6 | 2025 | 55 | 0.960 |
Why?
| | Postoperative Complications | 7 | 2021 | 2639 | 0.950 |
Why?
| | Retinal Diseases | 7 | 2025 | 91 | 0.940 |
Why?
| | Cataract Extraction | 4 | 2023 | 98 | 0.920 |
Why?
| | Glaucoma | 3 | 2023 | 234 | 0.910 |
Why?
| | Intraocular Pressure | 10 | 2024 | 305 | 0.910 |
Why?
| | Drug Costs | 2 | 2016 | 106 | 0.890 |
Why?
| | Retinal Vessels | 6 | 2021 | 69 | 0.870 |
Why?
| | Uveitis, Posterior | 5 | 2019 | 12 | 0.820 |
Why?
| | Methotrexate | 4 | 2025 | 260 | 0.810 |
Why?
| | Humans | 181 | 2025 | 136764 | 0.810 |
Why?
| | Anterior Chamber | 5 | 2021 | 22 | 0.810 |
Why?
| | Antirheumatic Agents | 2 | 2022 | 292 | 0.790 |
Why?
| | Inflammation | 10 | 2023 | 2834 | 0.790 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 5 | 0.790 |
Why?
| | Diabetic Retinopathy | 2 | 2022 | 189 | 0.790 |
Why?
| | Retinal Detachment | 3 | 2020 | 63 | 0.790 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2020 | 614 | 0.790 |
Why?
| | Eye Diseases | 10 | 2020 | 87 | 0.780 |
Why?
| | Retinitis | 15 | 1993 | 20 | 0.770 |
Why?
| | Azathioprine | 3 | 2025 | 54 | 0.770 |
Why?
| | Retrospective Studies | 36 | 2025 | 15504 | 0.770 |
Why?
| | Health Care Costs | 2 | 2016 | 384 | 0.760 |
Why?
| | Behcet Syndrome | 7 | 2021 | 18 | 0.760 |
Why?
| | Retinal Drusen | 4 | 2024 | 31 | 0.730 |
Why?
| | Drug Implants | 6 | 2024 | 82 | 0.730 |
Why?
| | Acquired Immunodeficiency Syndrome | 22 | 1996 | 230 | 0.720 |
Why?
| | Retinal Vasculitis | 1 | 2021 | 10 | 0.710 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.690 |
Why?
| | Autoimmune Diseases | 21 | 2025 | 460 | 0.650 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 44 | 0.650 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 75 | 0.630 |
Why?
| | Homosexuality, Male | 1 | 2020 | 184 | 0.620 |
Why?
| | Registries | 7 | 2025 | 2015 | 0.610 |
Why?
| | Ophthalmology | 4 | 2025 | 86 | 0.610 |
Why?
| | Complement Activation | 4 | 2025 | 410 | 0.600 |
Why?
| | Practice Patterns, Physicians' | 3 | 2016 | 1301 | 0.580 |
Why?
| | Follow-Up Studies | 18 | 2025 | 5106 | 0.570 |
Why?
| | Cytomegalovirus | 3 | 2022 | 157 | 0.560 |
Why?
| | International Classification of Diseases | 1 | 2018 | 132 | 0.560 |
Why?
| | Conjunctivitis | 3 | 2024 | 30 | 0.560 |
Why?
| | Surveys and Questionnaires | 8 | 2022 | 5742 | 0.550 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 224 | 0.540 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 37 | 0.540 |
Why?
| | Aged | 48 | 2025 | 23794 | 0.530 |
Why?
| | Labor, Induced | 1 | 2017 | 33 | 0.530 |
Why?
| | Sarcoidosis | 9 | 2023 | 159 | 0.530 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 556 | 0.530 |
Why?
| | Female | 109 | 2025 | 72787 | 0.520 |
Why?
| | Labor, Obstetric | 1 | 2017 | 61 | 0.520 |
Why?
| | Male | 93 | 2025 | 67309 | 0.520 |
Why?
| | Rheumatologists | 1 | 2016 | 16 | 0.520 |
Why?
| | Ophthalmologists | 1 | 2016 | 12 | 0.520 |
Why?
| | Adult | 76 | 2025 | 37630 | 0.510 |
Why?
| | Polychondritis, Relapsing | 1 | 2015 | 2 | 0.500 |
Why?
| | Middle Aged | 61 | 2025 | 33228 | 0.500 |
Why?
| | Ear Auricle | 1 | 2015 | 10 | 0.490 |
Why?
| | Insurance, Health | 2 | 2016 | 280 | 0.490 |
Why?
| | Vision Disorders | 2 | 2016 | 141 | 0.480 |
Why?
| | Neonatal Screening | 4 | 2018 | 169 | 0.470 |
Why?
| | Needles | 1 | 2015 | 59 | 0.470 |
Why?
| | Biopsy, Needle | 1 | 2015 | 189 | 0.460 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1571 | 0.460 |
Why?
| | Surgical Wound Infection | 1 | 2018 | 305 | 0.450 |
Why?
| | DNA, Viral | 1 | 2016 | 363 | 0.440 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 1032 | 0.440 |
Why?
| | Aged, 80 and over | 18 | 2025 | 7585 | 0.440 |
Why?
| | Biomarkers | 10 | 2025 | 4143 | 0.430 |
Why?
| | Multimodal Imaging | 2 | 2025 | 112 | 0.420 |
Why?
| | Choroid | 12 | 2024 | 62 | 0.420 |
Why?
| | Premature Birth | 1 | 2017 | 331 | 0.410 |
Why?
| | Immunosuppressive Agents | 6 | 2025 | 889 | 0.410 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1167 | 0.410 |
Why?
| | Cytomegalovirus Infections | 12 | 1999 | 192 | 0.400 |
Why?
| | Databases, Factual | 1 | 2018 | 1351 | 0.400 |
Why?
| | Vaccination | 1 | 2021 | 1376 | 0.390 |
Why?
| | Gestational Age | 8 | 2020 | 902 | 0.390 |
Why?
| | Melanoma | 1 | 2019 | 757 | 0.390 |
Why?
| | Bacteria | 2 | 2018 | 854 | 0.390 |
Why?
| | Colorado | 11 | 2025 | 4518 | 0.380 |
Why?
| | Antiviral Agents | 11 | 2022 | 739 | 0.380 |
Why?
| | Skin Neoplasms | 2 | 2019 | 852 | 0.370 |
Why?
| | Steroids | 2 | 2023 | 167 | 0.370 |
Why?
| | Intravitreal Injections | 2 | 2024 | 56 | 0.360 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 2122 | 0.360 |
Why?
| | Placenta | 1 | 2018 | 749 | 0.360 |
Why?
| | Anti-Bacterial Agents | 3 | 2024 | 1798 | 0.360 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2022 | 127 | 0.360 |
Why?
| | Fundus Oculi | 9 | 2025 | 65 | 0.350 |
Why?
| | Graft Rejection | 4 | 2025 | 620 | 0.350 |
Why?
| | Electronic Health Records | 1 | 2018 | 1046 | 0.350 |
Why?
| | Macula Lutea | 3 | 2020 | 21 | 0.340 |
Why?
| | Ciliary Body | 9 | 2018 | 39 | 0.340 |
Why?
| | Trabeculectomy | 2 | 2022 | 72 | 0.330 |
Why?
| | Complement Factor B | 2 | 2022 | 109 | 0.330 |
Why?
| | Organ Transplantation | 2 | 2024 | 248 | 0.320 |
Why?
| | Ganciclovir | 9 | 2022 | 53 | 0.310 |
Why?
| | United States | 12 | 2025 | 14691 | 0.310 |
Why?
| | Glaucoma, Open-Angle | 2 | 2022 | 103 | 0.300 |
Why?
| | Aqueous Humor | 4 | 2022 | 34 | 0.300 |
Why?
| | Adalimumab | 3 | 2025 | 48 | 0.300 |
Why?
| | Antigens | 14 | 1990 | 357 | 0.300 |
Why?
| | Disease Management | 2 | 2025 | 624 | 0.290 |
Why?
| | Complement System Proteins | 3 | 2022 | 327 | 0.290 |
Why?
| | Conjunctival Diseases | 3 | 2017 | 18 | 0.280 |
Why?
| | Eye Proteins | 7 | 1990 | 92 | 0.280 |
Why?
| | Adolescent | 29 | 2024 | 21382 | 0.280 |
Why?
| | Incidence | 7 | 2024 | 2792 | 0.280 |
Why?
| | Retinal Pigment Epithelium | 3 | 2024 | 77 | 0.280 |
Why?
| | Retina | 18 | 1993 | 298 | 0.270 |
Why?
| | Cyclosporine | 2 | 2022 | 268 | 0.270 |
Why?
| | Cross-Sectional Studies | 7 | 2024 | 5423 | 0.260 |
Why?
| | Risk Factors | 12 | 2025 | 10326 | 0.260 |
Why?
| | Mycophenolic Acid | 3 | 2025 | 117 | 0.260 |
Why?
| | Birth Weight | 4 | 2020 | 514 | 0.260 |
Why?
| | Corneal Diseases | 5 | 2017 | 34 | 0.260 |
Why?
| | Uveitis, Anterior | 4 | 2018 | 18 | 0.260 |
Why?
| | Time Factors | 13 | 2025 | 6806 | 0.250 |
Why?
| | Child | 22 | 2024 | 21822 | 0.250 |
Why?
| | Opportunistic Infections | 4 | 1991 | 45 | 0.240 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 2 | 2024 | 6 | 0.240 |
Why?
| | Biological Factors | 2 | 2022 | 39 | 0.240 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 43 | 0.240 |
Why?
| | Bromocriptine | 4 | 1990 | 29 | 0.240 |
Why?
| | Academies and Institutes | 1 | 2025 | 53 | 0.230 |
Why?
| | Withholding Treatment | 1 | 2025 | 76 | 0.230 |
Why?
| | Papilledema | 2 | 2024 | 39 | 0.220 |
Why?
| | Child, Preschool | 10 | 2024 | 11000 | 0.220 |
Why?
| | Young Adult | 8 | 2024 | 13129 | 0.220 |
Why?
| | Specialization | 2 | 2016 | 143 | 0.220 |
Why?
| | Tuberculosis, Ocular | 1 | 2024 | 8 | 0.220 |
Why?
| | Retinal Vein Occlusion | 1 | 2004 | 13 | 0.220 |
Why?
| | Laser Therapy | 5 | 2021 | 130 | 0.220 |
Why?
| | Interferon-gamma Release Tests | 1 | 2024 | 32 | 0.210 |
Why?
| | Infant | 9 | 2022 | 9398 | 0.210 |
Why?
| | Infant, Premature | 2 | 2019 | 566 | 0.210 |
Why?
| | Fluoresceins | 5 | 1989 | 47 | 0.210 |
Why?
| | Advisory Committees | 1 | 2025 | 219 | 0.210 |
Why?
| | Optic Disk | 1 | 2024 | 44 | 0.210 |
Why?
| | Cohort Studies | 7 | 2020 | 5701 | 0.210 |
Why?
| | Infant, Very Low Birth Weight | 3 | 2018 | 68 | 0.200 |
Why?
| | Phacoemulsification | 3 | 2019 | 122 | 0.200 |
Why?
| | Treatment Outcome | 11 | 2025 | 10744 | 0.200 |
Why?
| | Algorithms | 4 | 2018 | 1689 | 0.200 |
Why?
| | Etanercept | 1 | 2022 | 57 | 0.200 |
Why?
| | Anti-Inflammatory Agents | 3 | 2022 | 496 | 0.200 |
Why?
| | Histocompatibility Antigens Class II | 9 | 1994 | 367 | 0.200 |
Why?
| | Foscarnet | 4 | 1996 | 19 | 0.200 |
Why?
| | Quality of Life | 3 | 2023 | 2878 | 0.190 |
Why?
| | Eye Neoplasms | 3 | 2017 | 18 | 0.190 |
Why?
| | Reference Standards | 2 | 2022 | 186 | 0.190 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2024 | 543 | 0.180 |
Why?
| | Albumins | 1 | 2022 | 113 | 0.180 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.180 |
Why?
| | Eye Infections, Viral | 2 | 1991 | 9 | 0.180 |
Why?
| | Capsule Opacification | 1 | 2021 | 22 | 0.180 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.180 |
Why?
| | Tacrolimus | 1 | 2022 | 199 | 0.180 |
Why?
| | Rats, Inbred Lew | 18 | 1994 | 114 | 0.180 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.180 |
Why?
| | T-Lymphocytes, Helper-Inducer | 8 | 1994 | 137 | 0.180 |
Why?
| | Antibodies, Monoclonal | 12 | 2020 | 1430 | 0.170 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 1935 | 0.170 |
Why?
| | Laser Coagulation | 2 | 2018 | 68 | 0.170 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2020 | 17 | 0.170 |
Why?
| | Administration, Topical | 4 | 2016 | 149 | 0.160 |
Why?
| | Anemia, Sickle Cell | 1 | 2004 | 269 | 0.160 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.160 |
Why?
| | Endotoxins | 3 | 1991 | 220 | 0.160 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 39 | 0.160 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 25 | 0.160 |
Why?
| | Multiple Sclerosis | 3 | 2023 | 455 | 0.160 |
Why?
| | Canada | 1 | 2020 | 417 | 0.160 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 39 | 0.160 |
Why?
| | Infant, Newborn | 7 | 2020 | 6033 | 0.150 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 238 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 42 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1242 | 0.150 |
Why?
| | Acyclovir | 5 | 2001 | 101 | 0.150 |
Why?
| | Pyrimidinones | 1 | 2019 | 113 | 0.150 |
Why?
| | Prospective Studies | 8 | 2025 | 7572 | 0.150 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 146 | 0.150 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 56 | 0.150 |
Why?
| | Computer Systems | 1 | 2018 | 45 | 0.150 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 19 | 0.150 |
Why?
| | Viral Load | 2 | 2016 | 464 | 0.140 |
Why?
| | Organophosphonates | 1 | 1998 | 93 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 247 | 0.140 |
Why?
| | Decision Making | 2 | 2016 | 898 | 0.140 |
Why?
| | Disease-Free Survival | 1 | 2019 | 685 | 0.140 |
Why?
| | Rats | 25 | 2025 | 5639 | 0.140 |
Why?
| | Risk | 4 | 2018 | 908 | 0.140 |
Why?
| | Biological Products | 1 | 2021 | 215 | 0.140 |
Why?
| | Farber Lipogranulomatosis | 1 | 2017 | 4 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 330 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 188 | 0.140 |
Why?
| | Reoperation | 1 | 2020 | 573 | 0.130 |
Why?
| | Synovitis | 1 | 2017 | 27 | 0.130 |
Why?
| | Amnion | 1 | 2017 | 28 | 0.130 |
Why?
| | Arrestin | 13 | 1990 | 14 | 0.130 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2017 | 38 | 0.130 |
Why?
| | Parity | 1 | 2017 | 125 | 0.130 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 36 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1462 | 0.130 |
Why?
| | Medical Informatics | 1 | 2017 | 101 | 0.130 |
Why?
| | Herpes Zoster | 2 | 2009 | 316 | 0.130 |
Why?
| | Cicatrix | 1 | 2017 | 64 | 0.130 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 140 | 0.130 |
Why?
| | Arthritis | 1 | 2017 | 95 | 0.130 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1059 | 0.130 |
Why?
| | Transplantation, Homologous | 2 | 2016 | 415 | 0.120 |
Why?
| | Terminology as Topic | 1 | 2017 | 216 | 0.120 |
Why?
| | Lymphocytes | 9 | 1991 | 393 | 0.120 |
Why?
| | Recovery of Function | 1 | 2019 | 652 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2022 | 440 | 0.120 |
Why?
| | Microbiological Techniques | 1 | 2015 | 30 | 0.120 |
Why?
| | T-Lymphocytes | 12 | 2022 | 1990 | 0.120 |
Why?
| | Weight Gain | 2 | 2016 | 519 | 0.120 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 120 | 0.120 |
Why?
| | Infliximab | 3 | 2025 | 111 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 188 | 0.120 |
Why?
| | Endoscopy | 1 | 2018 | 318 | 0.120 |
Why?
| | Pregnancy | 2 | 2018 | 6728 | 0.110 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 316 | 0.110 |
Why?
| | Rheumatology | 1 | 2016 | 118 | 0.110 |
Why?
| | Phosphonoacetic Acid | 2 | 1991 | 10 | 0.110 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 155 | 0.110 |
Why?
| | Lymphocyte Activation | 8 | 1990 | 1141 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2016 | 562 | 0.110 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 382 | 0.110 |
Why?
| | Chorioretinitis | 2 | 1992 | 3 | 0.110 |
Why?
| | Toxoplasmosis, Ocular | 2 | 1994 | 2 | 0.110 |
Why?
| | Disease Progression | 4 | 2025 | 2750 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3264 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 319 | 0.100 |
Why?
| | Fetus | 1 | 2018 | 806 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 907 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 916 | 0.100 |
Why?
| | Lymphoma, B-Cell | 2 | 1993 | 106 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 1998 | 1090 | 0.100 |
Why?
| | Kidney Diseases | 6 | 1989 | 407 | 0.100 |
Why?
| | HIV-1 | 1 | 1998 | 863 | 0.100 |
Why?
| | Iris | 3 | 1991 | 19 | 0.100 |
Why?
| | Health Surveys | 1 | 2014 | 513 | 0.100 |
Why?
| | Patient Selection | 1 | 2016 | 690 | 0.100 |
Why?
| | Creatinine | 7 | 1992 | 499 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1127 | 0.100 |
Why?
| | HLA Antigens | 7 | 1991 | 237 | 0.100 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 1992 | 122 | 0.100 |
Why?
| | Pars Planitis | 1 | 1992 | 1 | 0.100 |
Why?
| | Risk Assessment | 2 | 2019 | 3432 | 0.100 |
Why?
| | Mothers | 1 | 2018 | 752 | 0.090 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 1991 | 8 | 0.090 |
Why?
| | Injections, Intravenous | 7 | 1999 | 206 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2024 | 236 | 0.090 |
Why?
| | Capillary Permeability | 2 | 1991 | 145 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 626 | 0.090 |
Why?
| | HIV | 4 | 2020 | 234 | 0.090 |
Why?
| | Animals | 35 | 2025 | 36823 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1682 | 0.080 |
Why?
| | Antigens, Surface | 3 | 1989 | 153 | 0.080 |
Why?
| | Cytophagaceae | 1 | 1990 | 1 | 0.080 |
Why?
| | Toxoplasma | 2 | 1994 | 42 | 0.080 |
Why?
| | Bacterial Infections | 3 | 1989 | 250 | 0.080 |
Why?
| | Capnocytophaga | 1 | 1990 | 2 | 0.080 |
Why?
| | Clinical Competence | 1 | 2018 | 1094 | 0.080 |
Why?
| | Granuloma | 4 | 2023 | 91 | 0.080 |
Why?
| | Urine | 1 | 1989 | 56 | 0.080 |
Why?
| | Antigens, Protozoan | 1 | 1989 | 24 | 0.080 |
Why?
| | Sebaceous Gland Neoplasms | 1 | 1989 | 2 | 0.080 |
Why?
| | Eyelid Neoplasms | 1 | 1989 | 10 | 0.080 |
Why?
| | Blood Chemical Analysis | 1 | 1989 | 99 | 0.080 |
Why?
| | Odds Ratio | 4 | 2019 | 1065 | 0.080 |
Why?
| | Drug Therapy, Combination | 5 | 1998 | 1062 | 0.070 |
Why?
| | Tonometry, Ocular | 2 | 2019 | 95 | 0.070 |
Why?
| | Eye | 7 | 1988 | 108 | 0.070 |
Why?
| | Postoperative Period | 2 | 2019 | 342 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2024 | 2052 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2019 | 851 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4281 | 0.070 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1987 | 20 | 0.070 |
Why?
| | Antibody Formation | 3 | 1985 | 298 | 0.070 |
Why?
| | Dextrans | 1 | 1987 | 84 | 0.070 |
Why?
| | Fanconi Syndrome | 1 | 1986 | 2 | 0.070 |
Why?
| | Autoantibodies | 6 | 1992 | 1496 | 0.060 |
Why?
| | Escherichia coli | 1 | 1991 | 806 | 0.060 |
Why?
| | Prednisolone | 2 | 2020 | 82 | 0.060 |
Why?
| | Cell Movement | 2 | 1988 | 965 | 0.060 |
Why?
| | Lymphocyte Transfusion | 1 | 1986 | 21 | 0.060 |
Why?
| | Immunoenzyme Techniques | 8 | 1991 | 219 | 0.060 |
Why?
| | Interferometry | 1 | 1985 | 4 | 0.060 |
Why?
| | Lasers | 2 | 1985 | 130 | 0.060 |
Why?
| | Phenotype | 4 | 2022 | 3188 | 0.060 |
Why?
| | Lenses, Intraocular | 2 | 2021 | 43 | 0.060 |
Why?
| | Electroretinography | 1 | 2025 | 48 | 0.060 |
Why?
| | Panophthalmitis | 1 | 1985 | 2 | 0.060 |
Why?
| | Lubricant Eye Drops | 1 | 2024 | 9 | 0.060 |
Why?
| | Uveomeningoencephalitic Syndrome | 3 | 1990 | 7 | 0.060 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 75 | 0.050 |
Why?
| | Protein S Deficiency | 1 | 2004 | 7 | 0.050 |
Why?
| | Choroiditis | 4 | 1991 | 6 | 0.050 |
Why?
| | Endemic Diseases | 1 | 2024 | 32 | 0.050 |
Why?
| | Biopsy | 5 | 1993 | 1124 | 0.050 |
Why?
| | Myopia | 1 | 1984 | 47 | 0.050 |
Why?
| | Microscopy, Electron | 8 | 1988 | 432 | 0.050 |
Why?
| | Viremia | 1 | 2024 | 138 | 0.050 |
Why?
| | Phagocyte Bactericidal Dysfunction | 1 | 1983 | 12 | 0.050 |
Why?
| | Tears | 4 | 1987 | 28 | 0.050 |
Why?
| | Tretinoin | 1 | 1984 | 123 | 0.050 |
Why?
| | Ophthalmia, Sympathetic | 3 | 1990 | 3 | 0.050 |
Why?
| | Retinal Artery | 2 | 1987 | 17 | 0.050 |
Why?
| | Keratoplasty, Penetrating | 2 | 1994 | 4 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2024 | 202 | 0.050 |
Why?
| | Immunologic Memory | 1 | 1985 | 353 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 216 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2024 | 179 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2829 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2020 | 3540 | 0.050 |
Why?
| | Immunohistochemistry | 6 | 1993 | 1733 | 0.050 |
Why?
| | Deltaretrovirus | 3 | 1986 | 12 | 0.050 |
Why?
| | Aneurysm | 1 | 1982 | 31 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 1989 | 938 | 0.050 |
Why?
| | Cavernous Sinus | 1 | 1981 | 19 | 0.050 |
Why?
| | 2-Aminopurine | 1 | 2001 | 9 | 0.050 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2001 | 5 | 0.050 |
Why?
| | Infusions, Intravenous | 2 | 2020 | 412 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 167 | 0.040 |
Why?
| | Arteriovenous Fistula | 1 | 1981 | 36 | 0.040 |
Why?
| | Transplantation Tolerance | 1 | 2021 | 36 | 0.040 |
Why?
| | Pigment Epithelium of Eye | 4 | 1990 | 35 | 0.040 |
Why?
| | Abatacept | 1 | 2021 | 53 | 0.040 |
Why?
| | Tertiary Healthcare | 1 | 2020 | 33 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 56 | 0.040 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 8 | 0.040 |
Why?
| | Gonioscopy | 1 | 2020 | 7 | 0.040 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 15 | 0.040 |
Why?
| | Mycobacterium tuberculosis | 1 | 2024 | 310 | 0.040 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 29 | 0.040 |
Why?
| | Amyloidosis | 1 | 2020 | 42 | 0.040 |
Why?
| | Epithelium | 6 | 1991 | 311 | 0.040 |
Why?
| | Kidney | 3 | 1989 | 1467 | 0.040 |
Why?
| | Carotid Arteries | 1 | 1981 | 206 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 93 | 0.040 |
Why?
| | Immunization, Passive | 3 | 1988 | 90 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 343 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 408 | 0.040 |
Why?
| | Sarcoma, Kaposi | 4 | 1999 | 81 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 663 | 0.040 |
Why?
| | Cornea | 4 | 1989 | 137 | 0.040 |
Why?
| | Cytosine | 1 | 1998 | 49 | 0.040 |
Why?
| | Trabecular Meshwork | 1 | 2019 | 79 | 0.040 |
Why?
| | Hypertension | 5 | 1991 | 1284 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2022 | 0.040 |
Why?
| | Prolactin | 2 | 1988 | 96 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 269 | 0.040 |
Why?
| | Conjunctiva | 3 | 1989 | 51 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 78 | 0.040 |
Why?
| | Logistic Models | 2 | 2019 | 2067 | 0.040 |
Why?
| | Retinol-Binding Proteins | 2 | 1988 | 18 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2020 | 504 | 0.030 |
Why?
| | Fluorometholone | 1 | 2017 | 4 | 0.030 |
Why?
| | Drug Evaluation | 2 | 1988 | 84 | 0.030 |
Why?
| | Group Processes | 1 | 2017 | 62 | 0.030 |
Why?
| | Administration, Oral | 3 | 1999 | 813 | 0.030 |
Why?
| | North America | 1 | 2018 | 312 | 0.030 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2017 | 33 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 1987 | 136 | 0.030 |
Why?
| | HLA-DR Antigens | 5 | 1991 | 228 | 0.030 |
Why?
| | Interferon-gamma | 2 | 1991 | 788 | 0.030 |
Why?
| | Cattle | 5 | 1991 | 981 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 341 | 0.030 |
Why?
| | Cytokines | 1 | 2025 | 2083 | 0.030 |
Why?
| | Properdin | 1 | 1976 | 9 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 759 | 0.030 |
Why?
| | Rats, Inbred Strains | 5 | 1987 | 362 | 0.030 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 20 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 545 | 0.030 |
Why?
| | Plasma Cells | 2 | 1987 | 71 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 1996 | 71 | 0.030 |
Why?
| | Proteins | 2 | 2020 | 1008 | 0.030 |
Why?
| | Magnesium | 2 | 1986 | 156 | 0.030 |
Why?
| | Chronic Disease | 4 | 1990 | 1784 | 0.030 |
Why?
| | Syndrome | 2 | 1987 | 357 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1507 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 657 | 0.030 |
Why?
| | HIV Infections | 1 | 2009 | 2828 | 0.030 |
Why?
| | Blood Proteins | 2 | 1989 | 252 | 0.030 |
Why?
| | Glycoproteins | 1 | 1976 | 342 | 0.030 |
Why?
| | Conjunctival Neoplasms | 2 | 1984 | 8 | 0.030 |
Why?
| | Retinal Hemorrhage | 2 | 1986 | 19 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 1988 | 1481 | 0.030 |
Why?
| | Recurrence | 2 | 1988 | 1055 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 253 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1109 | 0.030 |
Why?
| | Granulomatous Disease, Chronic | 2 | 1983 | 55 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 4 | 1989 | 388 | 0.030 |
Why?
| | Antibodies, Antinuclear | 2 | 1992 | 71 | 0.030 |
Why?
| | Models, Biological | 2 | 2016 | 1773 | 0.020 |
Why?
| | Immunity, Cellular | 2 | 1985 | 268 | 0.020 |
Why?
| | Immunization | 2 | 1985 | 411 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 1994 | 385 | 0.020 |
Why?
| | Dinoprostone | 2 | 1990 | 191 | 0.020 |
Why?
| | Eye Infections | 1 | 1992 | 2 | 0.020 |
Why?
| | Cells, Cultured | 5 | 1991 | 4190 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1283 | 0.020 |
Why?
| | Cell Line | 5 | 1991 | 2837 | 0.020 |
Why?
| | Models, Statistical | 1 | 2016 | 667 | 0.020 |
Why?
| | Kinetics | 2 | 1988 | 1663 | 0.020 |
Why?
| | Epitopes | 3 | 1990 | 477 | 0.020 |
Why?
| | Propionibacterium acnes | 1 | 1991 | 10 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 98 | 0.020 |
Why?
| | Indomethacin | 2 | 1990 | 81 | 0.020 |
Why?
| | Sepsis | 2 | 1984 | 614 | 0.020 |
Why?
| | Transforming Growth Factor beta | 2 | 1991 | 480 | 0.020 |
Why?
| | Biological Transport, Active | 1 | 1991 | 77 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2822 | 0.020 |
Why?
| | Dogs | 2 | 1990 | 411 | 0.020 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 1990 | 7 | 0.020 |
Why?
| | Microcirculation | 1 | 1991 | 146 | 0.020 |
Why?
| | B-Lymphocytes | 2 | 1987 | 846 | 0.020 |
Why?
| | Random Allocation | 2 | 1988 | 353 | 0.020 |
Why?
| | Coronary Circulation | 1 | 1991 | 140 | 0.020 |
Why?
| | Endothelium, Corneal | 1 | 1990 | 16 | 0.020 |
Why?
| | Cefazolin | 1 | 1990 | 21 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 1991 | 1350 | 0.020 |
Why?
| | Fluorescein | 1 | 1989 | 25 | 0.020 |
Why?
| | Protein Binding | 2 | 1989 | 2216 | 0.020 |
Why?
| | Keratitis | 2 | 1994 | 15 | 0.020 |
Why?
| | Kidney Function Tests | 2 | 1989 | 159 | 0.020 |
Why?
| | Flow Cytometry | 2 | 1992 | 1177 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 1989 | 171 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 1990 | 170 | 0.020 |
Why?
| | Retroviridae Proteins | 1 | 1989 | 11 | 0.020 |
Why?
| | Hemocyanins | 2 | 1988 | 62 | 0.020 |
Why?
| | Antimetabolites | 1 | 1989 | 23 | 0.020 |
Why?
| | Alkylating Agents | 1 | 1989 | 24 | 0.020 |
Why?
| | Drug Eruptions | 1 | 1989 | 27 | 0.020 |
Why?
| | Heptanoates | 1 | 1988 | 2 | 0.020 |
Why?
| | Interferon Type I | 1 | 1990 | 140 | 0.020 |
Why?
| | Suramin | 1 | 1988 | 8 | 0.020 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1989 | 38 | 0.020 |
Why?
| | Candidiasis | 1 | 1989 | 56 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 1989 | 60 | 0.020 |
Why?
| | Lung Diseases | 2 | 1986 | 767 | 0.020 |
Why?
| | Toxoplasmosis | 1 | 1989 | 40 | 0.020 |
Why?
| | Receptors, Virus | 1 | 1989 | 83 | 0.020 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 1989 | 84 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 1988 | 66 | 0.020 |
Why?
| | Mycobacterium Infections | 1 | 1989 | 63 | 0.020 |
Why?
| | Placebos | 1 | 1988 | 199 | 0.020 |
Why?
| | Lens, Crystalline | 1 | 1990 | 125 | 0.020 |
Why?
| | Injections | 1 | 1989 | 183 | 0.020 |
Why?
| | Corneal Injuries | 1 | 1989 | 44 | 0.020 |
Why?
| | Antigen-Antibody Complex | 2 | 1985 | 90 | 0.020 |
Why?
| | Central Nervous System Diseases | 1 | 1989 | 69 | 0.020 |
Why?
| | Dexamethasone | 2 | 1987 | 368 | 0.020 |
Why?
| | Sugar Alcohol Dehydrogenases | 1 | 1987 | 2 | 0.020 |
Why?
| | HIV Seropositivity | 1 | 1989 | 125 | 0.020 |
Why?
| | Imidazolidines | 1 | 1987 | 10 | 0.020 |
Why?
| | Elapid Venoms | 1 | 1987 | 18 | 0.020 |
Why?
| | Colchicine | 1 | 1987 | 23 | 0.020 |
Why?
| | Blood-Retinal Barrier | 1 | 1987 | 15 | 0.020 |
Why?
| | Aldehyde Reductase | 1 | 1987 | 29 | 0.020 |
Why?
| | Specific Gravity | 1 | 1987 | 11 | 0.020 |
Why?
| | Community Health Services | 1 | 2009 | 227 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 1 | 1987 | 66 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 1987 | 83 | 0.020 |
Why?
| | Galactosemias | 1 | 1987 | 16 | 0.020 |
Why?
| | Prednisone | 2 | 1986 | 239 | 0.020 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 1987 | 6 | 0.020 |
Why?
| | Pituitary-Adrenal System | 1 | 1989 | 162 | 0.020 |
Why?
| | Herpesviridae Infections | 1 | 1989 | 146 | 0.020 |
Why?
| | Onchocerciasis | 1 | 1987 | 7 | 0.020 |
Why?
| | Drug Interactions | 1 | 1989 | 407 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 656 | 0.020 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1989 | 197 | 0.020 |
Why?
| | Organ Specificity | 1 | 1987 | 304 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 1990 | 558 | 0.020 |
Why?
| | Molecular Weight | 1 | 1987 | 335 | 0.020 |
Why?
| | Sclera | 1 | 1987 | 36 | 0.020 |
Why?
| | Heart Rate | 1 | 1991 | 820 | 0.020 |
Why?
| | Macaca mulatta | 1 | 1987 | 166 | 0.020 |
Why?
| | Dihydroergotoxine | 1 | 1986 | 1 | 0.020 |
Why?
| | Indium | 1 | 1986 | 9 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 1990 | 886 | 0.020 |
Why?
| | Imidazoles | 1 | 1987 | 238 | 0.020 |
Why?
| | Radioisotopes | 1 | 1986 | 31 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1987 | 216 | 0.020 |
Why?
| | Muramidase | 1 | 1986 | 77 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 1986 | 31 | 0.020 |
Why?
| | Wound Healing | 1 | 1989 | 328 | 0.020 |
Why?
| | Serum Albumin | 1 | 1986 | 150 | 0.020 |
Why?
| | Immune Tolerance | 1 | 1988 | 362 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3946 | 0.020 |
Why?
| | Reference Values | 4 | 1989 | 816 | 0.020 |
Why?
| | Osteoporosis | 1 | 1989 | 243 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 703 | 0.020 |
Why?
| | Vascular Diseases | 1 | 1988 | 243 | 0.010 |
Why?
| | Connective Tissue | 1 | 1985 | 36 | 0.010 |
Why?
| | Double-Blind Method | 3 | 2001 | 1981 | 0.010 |
Why?
| | Acute Disease | 2 | 1987 | 1004 | 0.010 |
Why?
| | Prognosis | 2 | 1985 | 4013 | 0.010 |
Why?
| | Tetanus Toxoid | 1 | 1985 | 35 | 0.010 |
Why?
| | Rabbits | 1 | 1986 | 792 | 0.010 |
Why?
| | Pigmentation Disorders | 1 | 1985 | 9 | 0.010 |
Why?
| | Antibodies | 1 | 1987 | 410 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1985 | 330 | 0.010 |
Why?
| | Retinitis Pigmentosa | 1 | 1984 | 20 | 0.010 |
Why?
| | Salmonella typhimurium | 1 | 1986 | 183 | 0.010 |
Why?
| | Potassium | 1 | 1985 | 147 | 0.010 |
Why?
| | Lymphadenitis | 1 | 1984 | 6 | 0.010 |
Why?
| | Blood Sedimentation | 1 | 1984 | 39 | 0.010 |
Why?
| | Kidney Glomerulus | 1 | 1985 | 114 | 0.010 |
Why?
| | Chlorides | 1 | 1985 | 136 | 0.010 |
Why?
| | Kidney Tubules, Proximal | 1 | 1985 | 127 | 0.010 |
Why?
| | Fibrosis | 1 | 1987 | 551 | 0.010 |
Why?
| | Isotretinoin | 1 | 1984 | 26 | 0.010 |
Why?
| | Oculomotor Muscles | 1 | 1984 | 40 | 0.010 |
Why?
| | Acne Vulgaris | 1 | 1984 | 28 | 0.010 |
Why?
| | Complement C3 | 1 | 1985 | 209 | 0.010 |
Why?
| | Uveal Diseases | 1 | 1983 | 5 | 0.010 |
Why?
| | Optic Neuritis | 1 | 1984 | 41 | 0.010 |
Why?
| | Peptides | 1 | 1990 | 979 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2009 | 780 | 0.010 |
Why?
| | Chediak-Higashi Syndrome | 1 | 1983 | 7 | 0.010 |
Why?
| | Uric Acid | 1 | 1984 | 163 | 0.010 |
Why?
| | Rats, Inbred BN | 2 | 1994 | 58 | 0.010 |
Why?
| | Carbon Dioxide | 1 | 1985 | 267 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1984 | 136 | 0.010 |
Why?
| | Anemia | 1 | 1984 | 170 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 1989 | 566 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1986 | 1231 | 0.010 |
Why?
| | Liver Diseases | 1 | 1986 | 311 | 0.010 |
Why?
| | Fluorometry | 1 | 1981 | 17 | 0.010 |
Why?
| | Immunochemistry | 3 | 1986 | 14 | 0.010 |
Why?
| | Melanosis | 1 | 1981 | 16 | 0.010 |
Why?
| | Computers | 1 | 1981 | 70 | 0.010 |
Why?
| | Histocytochemistry | 3 | 1986 | 79 | 0.010 |
Why?
| | Liver | 1 | 1990 | 1940 | 0.010 |
Why?
| | Eyelid Diseases | 1 | 1981 | 19 | 0.010 |
Why?
| | Edema | 1 | 1982 | 129 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1985 | 887 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2001 | 328 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1197 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1994 | 173 | 0.010 |
Why?
| | HLA-DQ Antigens | 2 | 1991 | 181 | 0.010 |
Why?
| | Protease Inhibitors | 1 | 1999 | 107 | 0.010 |
Why?
| | Permeability | 2 | 1987 | 161 | 0.010 |
Why?
| | Arthus Reaction | 2 | 1987 | 8 | 0.010 |
Why?
| | Sucrose | 2 | 1987 | 110 | 0.010 |
Why?
| | Photoreceptor Cells | 2 | 1987 | 17 | 0.010 |
Why?
| | Survival Analysis | 1 | 1999 | 1321 | 0.010 |
Why?
| | Immunologic Techniques | 2 | 1986 | 40 | 0.010 |
Why?
| | Macrophages | 2 | 1994 | 1544 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 1994 | 17 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1994 | 72 | 0.010 |
Why?
| | DNA, Protozoan | 1 | 1994 | 31 | 0.010 |
Why?
| | Tissue Donors | 2 | 1989 | 417 | 0.010 |
Why?
| | Shock, Septic | 1 | 1976 | 219 | 0.010 |
Why?
| | Eye Enucleation | 1 | 1993 | 12 | 0.010 |
Why?
| | Didanosine | 1 | 1993 | 13 | 0.010 |
Why?
| | Viral Proteins | 2 | 1985 | 340 | 0.010 |
Why?
| | Zidovudine | 1 | 1993 | 78 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1993 | 105 | 0.010 |
Why?
| | Mice | 2 | 1986 | 17733 | 0.010 |
Why?
| | Neutrophils | 2 | 1987 | 1236 | 0.010 |
Why?
| | Cell Cycle | 1 | 1994 | 601 | 0.010 |
Why?
| | HLA-DP Antigens | 1 | 1991 | 33 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1991 | 247 | 0.010 |
Why?
| | Thromboxane A2 | 1 | 1990 | 11 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 1990 | 126 | 0.010 |
Why?
| | Leukotriene B4 | 1 | 1990 | 42 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 1990 | 156 | 0.010 |
Why?
| | Biological Assay | 1 | 1991 | 123 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1990 | 173 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1990 | 90 | 0.010 |
Why?
| | Immunophenotyping | 1 | 1991 | 318 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 1990 | 148 | 0.000 |
Why?
| | Alanine Transaminase | 1 | 1990 | 157 | 0.000 |
Why?
| | Epoprostenol | 1 | 1990 | 136 | 0.000 |
Why?
| | T-Lymphocyte Subsets | 1 | 1992 | 417 | 0.000 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1992 | 242 | 0.000 |
Why?
| | Immunoglobulins | 1 | 1990 | 171 | 0.000 |
Why?
| | Coroners and Medical Examiners | 1 | 1989 | 8 | 0.000 |
Why?
| | Virus Cultivation | 1 | 1989 | 29 | 0.000 |
Why?
| | Adrenal Cortex | 1 | 1988 | 29 | 0.000 |
Why?
| | Methods | 1 | 1988 | 65 | 0.000 |
Why?
| | Chemical Fractionation | 1 | 1988 | 26 | 0.000 |
Why?
| | Survival Rate | 1 | 1993 | 1962 | 0.000 |
Why?
| | Arterioles | 1 | 1988 | 52 | 0.000 |
Why?
| | Metaraminol | 1 | 1987 | 1 | 0.000 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 1988 | 100 | 0.000 |
Why?
| | Rats, Inbred WKY | 1 | 1987 | 36 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1987 | 45 | 0.000 |
Why?
| | Peroxidases | 1 | 1987 | 34 | 0.000 |
Why?
| | Mannitol | 1 | 1987 | 38 | 0.000 |
Why?
| | Cell Membrane Permeability | 1 | 1987 | 78 | 0.000 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1988 | 89 | 0.000 |
Why?
| | Edetic Acid | 1 | 1987 | 50 | 0.000 |
Why?
| | Propionibacterium | 1 | 1986 | 2 | 0.000 |
Why?
| | AIDS-Related Complex | 1 | 1986 | 4 | 0.000 |
Why?
| | HIV Antigens | 1 | 1987 | 18 | 0.000 |
Why?
| | Serum Albumin, Bovine | 1 | 1987 | 63 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1988 | 329 | 0.000 |
Why?
| | Mitosis | 1 | 1988 | 192 | 0.000 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1986 | 41 | 0.000 |
Why?
| | Argon | 1 | 1986 | 21 | 0.000 |
Why?
| | Blood-Brain Barrier | 1 | 1987 | 138 | 0.000 |
Why?
| | Carcinoma | 1 | 1988 | 238 | 0.000 |
Why?
| | Cell Division | 1 | 1988 | 792 | 0.000 |
Why?
| | Interleukin-1 | 1 | 1990 | 964 | 0.000 |
Why?
| | Agranulocytosis | 1 | 1986 | 30 | 0.000 |
Why?
| | Antigens, Viral | 1 | 1987 | 178 | 0.000 |
Why?
| | Homosexuality | 1 | 1986 | 17 | 0.000 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1985 | 34 | 0.000 |
Why?
| | Hydrogen Peroxide | 1 | 1987 | 327 | 0.000 |
Why?
| | Amino Acid Sequence | 1 | 1990 | 2136 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1987 | 473 | 0.000 |
Why?
| | Light | 1 | 1988 | 378 | 0.000 |
Why?
| | Drug Synergism | 1 | 1986 | 382 | 0.000 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1986 | 184 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1990 | 2892 | 0.000 |
Why?
| | Autoantigens | 1 | 1988 | 428 | 0.000 |
Why?
| | Anterior Eye Segment | 1 | 1985 | 9 | 0.000 |
Why?
| | HLA-B27 Antigen | 1 | 1985 | 16 | 0.000 |
Why?
| | DNA | 1 | 1992 | 1458 | 0.000 |
Why?
| | Tissue and Organ Procurement | 1 | 1989 | 314 | 0.000 |
Why?
| | Pilot Projects | 1 | 1990 | 1692 | 0.000 |
Why?
| | Hyperemia | 1 | 1985 | 49 | 0.000 |
Why?
| | Biomarkers, Tumor | 1 | 1992 | 1272 | 0.000 |
Why?
| | Lymphokines | 1 | 1984 | 131 | 0.000 |
Why?
| | Gram-Negative Bacteria | 1 | 1985 | 73 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1986 | 570 | 0.000 |
Why?
| | Indians, North American | 1 | 1990 | 629 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1991 | 1094 | 0.000 |
Why?
| | Ischemia | 1 | 1987 | 407 | 0.000 |
Why?
| | Brain Neoplasms | 1 | 1993 | 1235 | 0.000 |
Why?
| | Monocytes | 1 | 1987 | 563 | 0.000 |
Why?
| | Hodgkin Disease | 1 | 1986 | 138 | 0.000 |
Why?
| | Cryptococcosis | 1 | 1984 | 27 | 0.000 |
Why?
| | Lymphatic Diseases | 1 | 1983 | 22 | 0.000 |
Why?
| | alpha 1-Antitrypsin | 1 | 1985 | 108 | 0.000 |
Why?
| | Prevalence | 1 | 1990 | 2711 | 0.000 |
Why?
| | Clone Cells | 1 | 1984 | 263 | 0.000 |
Why?
| | Pain | 1 | 1988 | 754 | 0.000 |
Why?
| | Colitis | 1 | 1986 | 266 | 0.000 |
Why?
| | Meningitis | 1 | 1984 | 79 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1986 | 624 | 0.000 |
Why?
| | Microscopy, Fluorescence | 1 | 1984 | 396 | 0.000 |
Why?
| | Endothelium, Vascular | 1 | 1988 | 926 | 0.000 |
Why?
| | Vasodilation | 1 | 1985 | 496 | 0.000 |
Why?
| | Kidney Transplantation | 1 | 1988 | 701 | 0.000 |
Why?
| | Mice, Inbred BALB C | 1 | 1984 | 1269 | 0.000 |
Why?
| | Biomechanical Phenomena | 1 | 1985 | 806 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1986 | 1044 | 0.000 |
Why?
| | Pneumonia, Viral | 1 | 1986 | 368 | 0.000 |
Why?
| | Blood Pressure | 1 | 1987 | 1774 | 0.000 |
Why?
| | Killer Cells, Natural | 1 | 1983 | 442 | 0.000 |
Why?
| | Sexual Behavior | 1 | 1984 | 483 | 0.000 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1984 | 360 | 0.000 |
Why?
| | Lung | 1 | 1985 | 4052 | 0.000 |
Why?
|
|
Palestine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|